Physician profile
Michael Simonson
NPI 1356875967
$1,689.27
in general payments reported to CMS, 2019-2025
24 companies · $813 in 2025
The $813 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.81 · 2022: $73.68 · 2023: $107 · 2024: $630 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $519.53 | 2023-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $433.96 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $111.90 | 2025 | |
| Dexcom, INC. | $56.40 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $53.01 | 2024-2025 | Mounjaro, Zepbound |
| Abiomed | $50.56 | 2025 | |
| Inspire Medical Systems, INC. | $42.21 | 2025 | Inspire |
| Exact Sciences Corporation | $39.30 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $38.15 | 2025 | Ozempic |
| Sumitomo Pharma America, INC. | $37.05 | 2024 | Gemtesa |
| Aimmune Therapeutics, INC. | $36.98 | 2024-2025 | Zenpep |
| Ascensia Diabetes Care US INC. | $34.59 | 2024-2025 | |
| Neos Therapeutics, LP | $28.90 | 2024-2025 | Adzenys Xr-Odt |
| Biohaven Pharmaceuticals, INC. | $26.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.75 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $23.25 | 2021 | |
| Optinose US, INC. | $22.06 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.86 | 2024 | |
| Astellas Pharma US INC | $18.24 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $16.37 | 2021 | |
| Aytu Biopharma, INC. | $14.56 | 2024 | Karbinal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.45 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.40 | 2024 | Voquezna |
| Abbott Laboratories | $12.60 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Simonson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.